- Home
- CUE vs MOLN Comparison
CUE vs MOLN Comparison
Compare CUE & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CUE | MOLN |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.5M | 143.3M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CUE | MOLN |
|---|---|---|
| Price | $31.26 | $3.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $120.00 | $8.38 |
| AVG Volume (30 Days) | ★ 115.0K | 9.8K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,466,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 195.75 | N/A |
| 52 Week Low | $0.17 | $3.41 |
| 52 Week High | $45.50 | $5.36 |
Technical Indicators
Market Signals| Indicator | CUE | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 53.29 | 47.23 |
| Support Level | $23.88 | $3.62 |
| Resistance Level | $32.82 | $3.96 |
| Average True Range (ATR) | 4.68 | 0.12 |
| MACD | -0.52 | 0.01 |
| Stochastic Oscillator | 26.82 | 39.60 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.